Dit aandeel moet toch ooit eens uitbreken:
we staan nog steeds maar op 1.2 cent voor de R/S (1/40)
NITE 0.57 25
UBSS 0.59 128
CSTI 0.6 25
ETRF 0.66 25
ATDF 0.93 25
PUMA 1.1 5
March 30, 2012: The Company plans to seek short-term financing, which may be from a related party, to support minimal operations while the Company explores alternative sources of financing in order to continue its efforts to enter into an arrangement to support the continued development of its picoplatin product candidate.
In November 2011, VSTM entered into a license agreement with Poniard under which VSTM acquired an exclusive, worldwide license under patent rights and know-how owned or controlled by Poniard to develop, make, use and sell compounds and products covered by the licensed patent rights for the diagnosis, treatment, prevention or control of all human diseases and conditions.
Under the agreement, VSTM paid Poniard an upfront license fee and agreed to pay Poniard milestone payments of up to an aggregate of $13,250,000 upon the achievement of specified development and regulatory milestones. VSTM also agreed to issue to Poniard a warrant to purchase 142,857 shares of common stock upon the first dosing of the first patient in VSTM's first Phase 1 clinical trial of a licensed product.